Author Contributions Conceived and designed the experiments: ML MEH WH TH. Performed the experiments: WH TH CC YY PZ XQ ZL YZ BZ. Analyzed the data: References 1. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese ‘‘Thunder of God Vine,’’ is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66(9): 4758–65. 2. Antonoff MB, Chugh R, Borja-Cacho D, Dudeja V, Clawson KA, et al. (2009) Triptolide Therapy for Neuroblastoma Decreases Cell Viability in Vitro and Inhibits Tumor Growth in Vivo. Surgery 146(2): 282–290. 3. Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, et al. (2009) Effects of triptolide from Tripterygium wilfordii on ER [alpha] and p53 expression in two human breast cancer cell lines. Phytomedicine 16(11): 1006–13. 4. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, et al. (2007) Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 67(19): 9407–16. 5. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM (2002) Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 8(8): 2666–74. 6. Westerheide SD, Kawahara TL, Orton K, Morimoto RI (2006) Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 281(14): 9616–22. 7. Wang Z, Jin H, Xu R, Mei Q, Fan D (2009) Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med 41(10): 717–27. 8. Zhu W, Ou Y, Li Y, Xiao R, Shu M, et al. (2009) A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 75(4): 812–9. 9. Yang S, Chen J, Guo Z, Xu XM, Wang L, et al. (2003) Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2(1): 65–72. 10. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, et al. (2001) Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 276(3): 2221–7. 11. Hay RT (2005) SUMO: A History of Modification. Mol Cell 18: 1–12. 12. Cheng J, Kang X, Zhang S, Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131(3): 584–95. 13. Mikolajczyk J, Drag M, Be´ke´s Ms, Cao JT, Ronai Z, et al. (2007) Small Ubiquitin-related Modifier (SUMO)-specific Proteases. J Biol Chem 282(36): 26217–24. 14. Sarge KD, Park-Sarge OK (2009) Sumoylation and human disease pathogen- esis. Trends Biochem Sci 34(4): 200–5. 15. Cheng J, Bawa T, Lee P, Gong L, Yeh ET (2006) Role of Desumoylation in the Development of Prostate Cancer. Neoplasia 8(8): 667–76. 16. Karamouzis M (2008) SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 107(2): 195–210. 17. Cheng J, Wang D, Wang Z, Yeh ET (2004) SENP1 Enhances Androgen Receptor-Dependent Transcription through Desumoylation of Histone Deace- tylase 1. Mol Cell Biol 24(13): 6021–8. 18. Cheng J, Perkins ND, Yeh ET (2005) Differential Regulation of c-Jun-dependent Transcription by SUMO-specific Proteases. J Biol Chem 280(15): 14492–8. 19. Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, et al. (1997) Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer lett 112(1): 113–7. 20. Suzuki T, Ichiyama A, Saitoh H, Kawakami T, Omata M, et al. (1999) A new 30-kDa ubiquitin-related SUMO-1 hydrolase from bovine brain. J Biol Chem 274(44): 31131–4. 21. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARa through a SUMO-triggered RNF4/ ubiquitin-mediated pathway. Nat Cell Biol 10(5): 547–55. 22. Heinlein CA, Chang CH (2004) Androgen Receptor in Prostate Cancer. Endocr Rev 25: 2276–308. 23. Zoran C, Helmut K, Georg B, Hannes S, Alfred H (2003) Androgen Receptors in Prostate Cancer. J Urol 170(4): 1363–9. 24. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361(9361): 955–64. 25. Cai CM, Hsieh CL, Shemshedini L (2007) c-Jun Has Multiple Enhancing Activities in the Novel Cross Talk between the Androgen Receptor and Ets Variant Gene 1 in Prostate Cancer. Mol Cancer Res 5(7): 725–35. 26. Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell- proliferation and transformation. Biochim Biophys Acta 1072: 129–57. 27. Gottlicher M, Heck S, Herrlich P (1988) Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 76(7): 480–9. 28. Jang SY, Jang SW, Ko J (2011) Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett 300(1): 57–65. Triptolide Inhibits PCa Cells Proliferation ML WH TH CC PZ XQ. Contributed reagents/materials/analysis tools: JW LL CS HL KG SZ LY. Wrote the paper: WH TH MEH ML. 29. Zhang T, Hamza A, Cao XH, Wang B, Yu SW, et al. (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7(1): 162–70. 30. Dai Y, DeSano J, Tang WH, Meng XJ, Meng Y, et al. (2010) Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB. PLoS One 5(12): e14153. 31. Li W, Liu Y, Li XX, Yu Y, Wu JJ, et al. (2011) MAPKs are not involved in Triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status. Planta Med 77: 27–31. 32. Titov DV, Gilman B, He QL, Bhat S, Low WK, et al. (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7(3): 182–8. 33. Annereau JP, Vispe´ S, Larrousse P, Filiol J, Gras S, et al. (2006) On the mechanism of action of triptolide, beyond the NF-kB pathway. Proc Amer Assoc Cancer Res 47, # 1366. 34. Wang X, Matta R, Shen G, Nelin LD, Pei D, at al (2006) Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Mol Med 84(5): 405–15. 35. Wan CK, Wang C, Cheung HY, Yang M, Fong WF (2006) Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett 241(1): 31–41. 36. Tan BJ, Tan BH, Chiu GN (2011) Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol Rep 26(5): 1315–21. 37. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM (2002) Antiproliferative and Proapoptotic Activities of Triptolide (PG490), a Natural Product Entering Clinical Trials, on Primary Cultures of Human Prostatic Epithelial Cells. Clin Cancer Res 8(8): 2666–74. 38. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7(1): 21–33. 39. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1): 37–50. 40. Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003) proteasome as a target for cancer therapy. Clin Cancer Res 9(17): 6316–25. 41. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3): 630–9. 42. Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Cancer Control 10(5): 361–9. 43. Boccadoro M, Morgan G, Cavenagh J (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5(18): 1–9. 44. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, et al. (2010) Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia. J Clin Oncol 28(8): 1422–8. 45. Petrie K, Zelent A (2008) Marked for death. Nat Cell Biol 10(5): 507–9. 46. Kim KI, Baek SH (2006) SUMOylation Code in Cancer Development and Metastasis. Mol Cells 22(3): 247–53. 47. Bawa-Khalfe T, Yeh ET (2010) SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 1(7): 748–52. 48. Kaikkonen S, Ja¨a¨skela¨inen T, Karvonen U, Rytinki MM, Makkonen H, et al. (2009) SUMO-Specific Protease 1 (SENP1) Reverses the Hormone-Augmented SUMOylation of Androgen Receptor and Modulates Gene Responses in Prostate Cancer Cells. Mol Endocrinol 23(3): 292–307. 49. Xu Y, Zuo Y, Zhang H, Kang X, Yue F, et al. (2010) Induction of SENP1 in Endothelial Cells Contributes to Hypoxia-driven VEGF Expression and Angiogenesis. J Biol Chem 285(47): 36682–8. 50. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001–15. 51. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, et al. (1996) Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2(5): 889–95. 52. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, et al. (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129–35. 53. Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23: 175–200. 54. McKenna NJ, Lanz RB, O’Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321–44. 55. Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET (2007) Induction of the SUMO- specific Protease 1 Transcription by the Androgen Receptor in Prostate Cancer Cells. J Biol Chem 282(52): 37341–9. 56. Shaulian E (2010) AP-1-The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 22(6): 894–9. PLoS ONE | www.plosone.org 16 May 2012 | Volume 7 | Issue 5 | e37693